AIDS and Immune System Collapse: Opportunistic Infections, Cancers, and Systemic Effects
HIV progressively depletes CD4+ T lymphocytes, the orchestrators of adaptive immunity. When CD4 count falls below 200 cells/μL (or an AIDS-defining illness occurs), the resulting immunodeficiency permits a spectrum of opportunistic diseases.
Opportunistic Infections (CD4-Dependent Risk)
| CD4 Range | Typical OIs |
| >500 | TB, bacterial pneumonia, HSV, VZV (shingles) |
| 200–500 | Oral/vaginal candidiasis, oral hairy leukoplakia (EBV), Kaposi sarcoma (HHV-8), cervical dysplasia (HPV) |
| <200 | PCP (Pneumocystis), Toxoplasma encephalitis, Cryptococcal meningitis, CMV retinitis/colitis, MAC disseminated |
| <100 | Progressive multifocal leukoencephalopathy (JCV), disseminated fungal (Histoplasma, Coccidioides), severe CMV |
| <50 | Disseminated MAC, CMV, Candida; lymphoma (CNS, systemic) |
AIDS-Defining Malignancies
- Kaposi sarcoma (HHV-8): Vascular tumors; skin, mucosa, viscera.
- Non-Hodgkin lymphoma (EBV-driven): Primary CNS lymphoma, Burkitt, DLBCL.
- Invasive cervical cancer (HPV): Accelerated progression.
Non-AIDS-Defining Cancers (Increased Incidence)
- Lung cancer (smoking synergy)
- Hepatocellular carcinoma (HBV/HCV coinfection)
- Anal cancer (HPV, MSM)
- Hodgkin lymphoma
Systemic Manifestations
- Wasting syndrome: >10% weight loss + diarrhea/weakness/fever >30 days.
- Neurocognitive: HAND (asymptomatic → mild → HIV dementia).
- Renal: HIVAN (collapsing FSGS), drug nephrotoxicity.
- Cardiovascular: Accelerated atherosclerosis (inflammation + ART metabolic effects).
- Bone: Osteoporosis, osteonecrosis (AVN).
- Hematologic: Anemia, neutropenia, thrombocytopenia.
ART Transforms Outcomes
Combination ART suppresses HIV RNA to <50 copies/mL, allowing CD4 recovery, immune reconstitution, and dramatic reduction in OIs, malignancies, and mortality. Life expectancy approaches normal with early, sustained treatment. "Undetectable = Untransmittable" (U=U).
Monitoring
- CD4 count and HIV viral load q3–6 months.
- OI prophylaxis: TMP-SMX (PCP, Toxo) if CD4 <200; azithromycin (MAC) if CD4 <50.
- Cancer screening per guidelines (earlier/more frequent).
HIV & AIDS - Related Articles